This invention discloses a universal influenza
virus-like particle (VLP) vaccine based on
glycosylation engineering optimization, its preparation method, and its application, belonging to the field of
biomedical technology. The vaccine contains an S399 glycosylated
mutant of the HA stem, a NA-HA1
fusion protein, and a Gag-5M2e
fusion protein containing M2e tandem variants of five influenza subtypes, prepared by expression in a stable CHO-
S cell line. Using the broad-spectrum
neutralizing antibody CR9114 as a target, the S399
mutant was obtained through molecular docking screening. A vector was constructed using the PhiC31 integration
system, and stable
cell lines were screened. Expression was optimized through
temperature control and ManNAc
glycosylation, combined with Core700
size exclusion chromatography and
heparin affinity chromatography for purification, resulting in high
recovery. The obtained VLP showed 41.13%
assembly integrity, a molecular weight of 4.27 MDa, a particle size of 120-124 nm, and good homogeneity. The vaccine is designed to deliver broad-spectrum neutralizing epitopes and multiple subtype antigens, with potential cross-protective
efficacy against H9N2, H1N1, H3N2, H7N9, and H5N1. It is suitable for the prevention and control of avian influenza in poultry and for
public health influenza reserves, providing a new solution for the large-scale production of broad-spectrum influenza vaccines.